# Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration

> **NCT07554222** · PHASE1 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Healthy
- Active Non-segmental Vitiligo
- Severe Alopecia Areata

## Interventions

- **DRUG:** placebo
- **DRUG:** Baricitinib tablets
- **DRUG:** IBI3013

## Key facts

- **NCT ID:** NCT07554222
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-18
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07554222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07554222, "Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07554222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*